Carrum Health, the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a consumer-driven platform for better, more cost-effective healthcare, has expanded its national reach with Mayo Clinic, one of the top hospital systems in the nation. Carrum Health patients will have access to high-quality joint and spine surgical care at Mayo Clinic locations in Jacksonville, Florida; Phoenix, Arizona; Rochester, Minnesota; and Scottsdale, Arizona.
Carrum Health has built a regionalized provider network in partnership with COEs across the country, using a rigorous and proprietary quality methodology that evaluates clinical performance at both the facility and surgeon level. Carrum Health chooses hospitals and surgical centers that are ranked at or near the top in their specialties, then directly connects them to patients needing the best possible care.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Self-insured employers, including several Fortune 500 companies, leverage Carrum Health’s technology-powered COE platform to avoid variation in the cost and quality of surgery and to deliver a superior patient experience. The platform enables employers to take advantage of transparent and predictable surgery pricing for an entire episode of care, like a hip or knee replacement, and works with providers to deliver high-quality and efficient care under a value-based care model. Employees and covered dependents at companies offering the Carrum Health surgery benefit have better access to world-class care through top institutions, such as Mayo Clinic. Carrum Health patients also often save thousands of dollars on their surgery because copays and coinsurance are 100 percent waived.
Oregon Health & Science University (OHSU) will begin offering Bright.md’s automated telehealth platform, SmartExam, to patients in October as part of the University’s Virtual Care Hub.
“In response to the COVID-19 pandemic, OHSU has dramatically expanded its ability to provide health care through telemedicine,” said Mark Lovgren, Interim VP of the Office of Digital Health at OHSU. “This collaboration is one more way in which we are ensuring our patients have access to the best possible health care from the comfort and security of their homes.”
SmartExam’s pre-built clinical content, protocol-driven modules, scalability, and automation that streamlines clinical workflows ensure providers have the tools they need to deliver high-quality evidence-based care for hundreds of low-acuity conditions in a matter of minutes.
SmartExam guides patients through a dynamic, online medical interview about their current symptoms, medical history, and medications. Then the platform then automatically pulls information from the patient’s EHR and presents everything to a reviewing provider in a chart-ready SOAP note. The provider reviews the provisional diagnosis and treatment plan and can either approve or customize the plan, or escalate the patient to a higher modality of care if the complexity of the condition warrants it.
Truvian Sciences, a healthcare company at the intersection of diagnostics and consumer technology, today announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company’s Easy Check COVID-19 IgM/IgG antibody test. Truvian’s Easy Check test is being produced at mass scale at a US based manufacturing facility and will be available to healthcare practitioners immediately.
The test, which has been rigorously tested and validated by leading healthcare professionals and scientific experts at University of California San Diego (UCSD) and the University of Chicago, exceeds the current EUA requirements for current COVID-19 antibody tests by delivering a sensitivity rate of 98.44 percent and a specificity of 98.9 percent. Additionally, the cross-reactivity evaluation determined no cross-reactivity (0 percent) with HIV, Influenza A and B and several coronavirus strains. “Truvian’s Easy Check performed exceptionally well, with a robust sample set, in both our own studies, as well as the studies conducted by independent laboratories,” said Jeff Hawkins, President and Chief Executive Officer, Truvian Sciences. “With its consistent reproducibility, we are confident our testing solution, backed by the FDA’s EUA, will set a higher bar for COVID-19 antibody testing.”
Medtech business Neuropace, which developed an FDA-approved device neurostimulator to help prevent seizures, raised $67 million in a funding round led by Accelmed Partners with participation from an unnamed strategic investor, Revelation Partners, Soleus Capital, and returning investors KCK Group and OrbiMed Advisors. The financing includes $33 million of new equity capital and $34 million from convertible debt provided by current investors from a prior funding round. The device received approval in March this year. Click here to read more.
Picture: akindo, Getty Images
